Neuphoria Therapeutics Inc. NEUP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8,928.57% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8,928.57% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 8,928.57% | -- | -- | -- | -- |
| SG&A Expenses | -14.68% | 18.61% | -18.48% | 12.01% | -13.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.68% | -72.68% | -42.22% | 58.44% | 6.30% |
| Operating Income | 96.85% | -106.91% | 30.95% | -58.44% | -6.54% |
| Income Before Tax | 46.02% | -104.83% | 194.70% | -960.97% | -236.27% |
| Income Tax Expenses | 86.95% | 57.14% | -400.00% | 73.68% | -681.82% |
| Earnings from Continuing Operations | 44.79% | -104.48% | 195.92% | -1,130.93% | -230.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.79% | -104.48% | 195.92% | -1,130.93% | -230.62% |
| EBIT | 96.85% | -106.91% | 30.95% | -58.44% | -6.54% |
| EBITDA | 99.68% | -105.45% | 32.54% | -61.28% | -6.75% |
| EPS Basic | 80.59% | -101.42% | 133.31% | -612.54% | -39.38% |
| Normalized Basic EPS | 94.36% | -101.41% | 155.11% | -514.19% | 19.68% |
| EPS Diluted | 80.59% | -101.42% | 56.79% | -612.54% | -39.37% |
| Normalized Diluted EPS | 94.36% | -101.41% | 155.11% | -514.19% | 19.68% |
| Average Basic Shares Outstanding | 184.40% | 214.77% | 187.98% | 72.76% | 137.20% |
| Average Diluted Shares Outstanding | 184.40% | 214.77% | 187.98% | 72.76% | 137.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |